Effects of Anacetrapib in Patients with Atherosclerotic Vascular Disease

Louise Bowman; Jemma C Hopewell; Fang Chen; Karl Wallendszus; William Stevens; Rory Collins; Stephen D Wiviott; Christopher P Cannon; Eugene Braunwald; Emily Sammons; Martin J Landray; HPS3/TIMI55–REVEAL Collaborative Group; Erik Berg Schmidt; Pia Thisted Dinesen; Anders Gammelmark; Thomas Andersen Rix; Henrik Vadmann; Karen Petrea  Andersen; B. Christensen; Lotte Hessing Kobbelgaard; Birgitte Charlotte Mikkelsen; Mette Storgaard Pedersen; Christian Torp-Pedersen

doi:10.1056/NEJMoa1706444

Effects of Anacetrapib in Patients with Atherosclerotic Vascular Disease

Louise Bowman, Jemma C Hopewell, Fang Chen, Karl Wallendszus, William Stevens, Rory Collins, Stephen D Wiviott, Christopher P Cannon, Eugene Braunwald, Emily Sammons, Martin J Landray, HPS3/TIMI55–REVEAL Collaborative Group, Erik Berg Schmidt (Member of study group), Pia Thisted Dinesen (Member of study group), Anders Gammelmark (Member of study group), Thomas Andersen Rix (Member of study group), Henrik Vadmann (Member of study group), Karen Petrea Andersen (Member of study group), B. Christensen (Member of study group), Lotte Hessing Kobbelgaard (Member of study group)Birgitte Charlotte Mikkelsen, Mette Storgaard Pedersen, Christian Torp-Pedersen

Research output: Contribution to journal › Journal article › Research › peer-review

530 Citations (Scopus)

Original language	English
Journal	The New England Journal of Medicine
Volume	377
Issue number	13
Pages (from-to)	1217-1227
Number of pages	11
ISSN	0028-4793
DOIs	https://doi.org/10.1056/NEJMoa1706444
Publication status	Published - 28 Sep 2017

Keywords

Aged
Anticholesteremic Agents
Atherosclerosis
Cholesterol
Cholesterol Ester Transfer Proteins
Coronary Disease
Double-Blind Method
Drug Therapy, Combination
Female
Humans
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Incidence
Kaplan-Meier Estimate
Male
Medication Adherence
Middle Aged
Oxazolidinones
Clinical Trial, Phase III
Journal Article
Multicenter Study
Randomized Controlled Trial
Research Support, Non-U.S. Gov't

Access to Document

10.1056/NEJMoa1706444

Cite this

Bowman, L., Hopewell, J. C., Chen, F., Wallendszus, K., Stevens, W., Collins, R., Wiviott, S. D., Cannon, C. P., Braunwald, E., Sammons, E., Landray, M. J., HPS3/TIMI55–REVEAL Collaborative Group, Schmidt, E. B., Dinesen, P. T., Gammelmark, A., Rix, T. A., Vadmann, H., Andersen , K. P., Christensen, B., ... Torp-Pedersen, C. (2017). Effects of Anacetrapib in Patients with Atherosclerotic Vascular Disease. The New England Journal of Medicine, 377(13), 1217-1227. https://doi.org/10.1056/NEJMoa1706444

Bowman, Louise ; Hopewell, Jemma C ; Chen, Fang ; Wallendszus, Karl ; Stevens, William ; Collins, Rory ; Wiviott, Stephen D ; Cannon, Christopher P ; Braunwald, Eugene ; Sammons, Emily ; Landray, Martin J ; HPS3/TIMI55–REVEAL Collaborative Group ; Schmidt, Erik Berg ; Dinesen, Pia Thisted ; Gammelmark, Anders ; Rix, Thomas Andersen ; Vadmann, Henrik ; Andersen , Karen Petrea ; Christensen, B. ; Kobbelgaard, Lotte Hessing ; Mikkelsen, Birgitte Charlotte ; Pedersen, Mette Storgaard ; Torp-Pedersen, Christian. / Effects of Anacetrapib in Patients with Atherosclerotic Vascular Disease. In: The New England Journal of Medicine. 2017 ; Vol. 377, No. 13. pp. 1217-1227.

@article{61f03a60273e4656916b6eb2027d74ed,

title = "Effects of Anacetrapib in Patients with Atherosclerotic Vascular Disease",

keywords = "Aged, Anticholesteremic Agents, Atherosclerosis, Cholesterol, Cholesterol Ester Transfer Proteins, Coronary Disease, Double-Blind Method, Drug Therapy, Combination, Female, Humans, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Incidence, Kaplan-Meier Estimate, Male, Medication Adherence, Middle Aged, Oxazolidinones, Clinical Trial, Phase III, Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't",

author = "Louise Bowman and Hopewell, {Jemma C} and Fang Chen and Karl Wallendszus and William Stevens and Rory Collins and Wiviott, {Stephen D} and Cannon, {Christopher P} and Eugene Braunwald and Emily Sammons and Landray, {Martin J} and {HPS3/TIMI55–REVEAL Collaborative Group} and Schmidt, {Erik Berg} and Dinesen, {Pia Thisted} and Anders Gammelmark and Rix, {Thomas Andersen} and Henrik Vadmann and Andersen, {Karen Petrea} and B. Christensen and Kobbelgaard, {Lotte Hessing} and Mikkelsen, {Birgitte Charlotte} and Pedersen, {Mette Storgaard} and Christian Torp-Pedersen",

year = "2017",

month = sep,

day = "28",

doi = "10.1056/NEJMoa1706444",

language = "English",

volume = "377",

pages = "1217--1227",

journal = "The New England Journal of Medicine",

issn = "0028-4793",

publisher = "Massachusetts Medical Society",

number = "13",

}

Bowman, L, Hopewell, JC, Chen, F, Wallendszus, K, Stevens, W, Collins, R, Wiviott, SD, Cannon, CP, Braunwald, E, Sammons, E, Landray, MJ, HPS3/TIMI55–REVEAL Collaborative Group, Schmidt, EB, Dinesen, PT , Gammelmark, A, Rix, TA, Vadmann, H , Andersen , KP, Christensen, B, Kobbelgaard, LH, Mikkelsen, BC, Pedersen, MS & Torp-Pedersen, C 2017, 'Effects of Anacetrapib in Patients with Atherosclerotic Vascular Disease', The New England Journal of Medicine, vol. 377, no. 13, pp. 1217-1227. https://doi.org/10.1056/NEJMoa1706444

Effects of Anacetrapib in Patients with Atherosclerotic Vascular Disease. / Bowman, Louise; Hopewell, Jemma C; Chen, Fang; Wallendszus, Karl; Stevens, William; Collins, Rory; Wiviott, Stephen D; Cannon, Christopher P; Braunwald, Eugene; Sammons, Emily; Landray, Martin J; HPS3/TIMI55–REVEAL Collaborative Group; Schmidt, Erik Berg (Member of study group); Dinesen, Pia Thisted (Member of study group); Gammelmark, Anders (Member of study group); Rix, Thomas Andersen (Member of study group); Vadmann, Henrik (Member of study group); Andersen , Karen Petrea (Member of study group); Christensen, B. (Member of study group); Kobbelgaard, Lotte Hessing (Member of study group); Mikkelsen, Birgitte Charlotte (Member of study group); Pedersen, Mette Storgaard (Member of study group); Torp-Pedersen, Christian (Member of study group).

In: The New England Journal of Medicine, Vol. 377, No. 13, 28.09.2017, p. 1217-1227.

Research output: Contribution to journal › Journal article › Research › peer-review

TY - JOUR

T1 - Effects of Anacetrapib in Patients with Atherosclerotic Vascular Disease

AU - Bowman, Louise

AU - Hopewell, Jemma C

AU - Chen, Fang

AU - Wallendszus, Karl

AU - Stevens, William

AU - Collins, Rory

AU - Wiviott, Stephen D

AU - Cannon, Christopher P

AU - Braunwald, Eugene

AU - Sammons, Emily

AU - Landray, Martin J

AU - HPS3/TIMI55–REVEAL Collaborative Group

A2 - Schmidt, Erik Berg

A2 - Dinesen, Pia Thisted

A2 - Gammelmark, Anders

A2 - Rix, Thomas Andersen

A2 - Vadmann, Henrik

A2 - Andersen , Karen Petrea

A2 - Christensen, B.

A2 - Kobbelgaard, Lotte Hessing

A2 - Mikkelsen, Birgitte Charlotte

A2 - Pedersen, Mette Storgaard

A2 - Torp-Pedersen, Christian

PY - 2017/9/28

Y1 - 2017/9/28

KW - Aged

KW - Anticholesteremic Agents

KW - Atherosclerosis

KW - Cholesterol

KW - Cholesterol Ester Transfer Proteins

KW - Coronary Disease

KW - Double-Blind Method

KW - Drug Therapy, Combination

KW - Female

KW - Humans

KW - Hydroxymethylglutaryl-CoA Reductase Inhibitors

KW - Incidence

KW - Kaplan-Meier Estimate

KW - Male

KW - Medication Adherence

KW - Middle Aged

KW - Oxazolidinones

KW - Clinical Trial, Phase III

KW - Journal Article

KW - Multicenter Study

KW - Randomized Controlled Trial

KW - Research Support, Non-U.S. Gov't

U2 - 10.1056/NEJMoa1706444

DO - 10.1056/NEJMoa1706444

M3 - Journal article

C2 - 28847206

VL - 377

SP - 1217

EP - 1227

JO - The New England Journal of Medicine

JF - The New England Journal of Medicine

SN - 0028-4793

IS - 13

ER -

Effects of Anacetrapib in Patients with Atherosclerotic Vascular Disease

Keywords

Access to Document

Fingerprint

Cite this